Iruplinalkib Trial Results Unveiled at World Lung Cancer Conference 2024

During the World Conference on Lung Cancer held in San Diego from September 7-10, 2024, updated findings from the Phase II INTELLECT study were presented, focusing on the efficacy and safety of iruplinalkib tablets in patients with ALK-positive crizotinib-resistant non-small-cell lung cancer. The study, led by Prof. Yuankai Shi, included 146 subjects and reported a median overall survival of 41.79 months with a 63.7% objective response rate. The trial also highlighted significant results for patients with CNS metastasis, showing a median overall survival of 43.01 months and an objective response rate of 55.6%. The intracranial response rates were promising, with a 64.3% iORR among those with measurable intracranial lesions. These findings underscore the potential of iruplinalkib as a viable treatment option for this challenging patient population. Safety data indicated a high incidence of treatment-related adverse events, with 93.8% of patients experiencing some form of side effect. However, no new safety signals were identified, suggesting that iruplinalkib maintains a manageable safety profile over the long term. The most common adverse events included elevated liver enzymes and hypercholesterolemia. The results presented at the conference reinforce the role of iruplinalkib in treating advanced NSCLC, particularly in patients who have developed resistance to crizotinib. This study contributes to the growing body of evidence supporting targeted therapies in oncology, offering hope for improved outcomes in a difficult-to-treat patient demographic.